Compare TMDX & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMDX | ACLX |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.2B |
| IPO Year | 2019 | 2022 |
| Metric | TMDX | ACLX |
|---|---|---|
| Price | $136.66 | $68.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $133.00 | $115.50 |
| AVG Volume (30 Days) | 835.5K | ★ 1.2M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.70 | N/A |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $566,354,000.00 | $35,898,000.00 |
| Revenue This Year | $38.84 | N/A |
| Revenue Next Year | $20.43 | $302.49 |
| P/E Ratio | $53.83 | ★ N/A |
| Revenue Growth | ★ 41.20 | N/A |
| 52 Week Low | $55.00 | $47.86 |
| 52 Week High | $156.00 | $94.07 |
| Indicator | TMDX | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 33.01 |
| Support Level | $133.50 | $66.00 |
| Resistance Level | $156.00 | $75.03 |
| Average True Range (ATR) | 8.50 | 5.23 |
| MACD | 0.41 | -1.69 |
| Stochastic Oscillator | 55.98 | 12.96 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.